Annual Uterine Cancer Symposium

年度子宫癌研讨会

• 批准号: 6943173
• 负责人: Karen Hsieh Lu
• 金额: $ 0.6万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-01 至 2009-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6943173
• 关键词: cancer prevention; chemoprevention; endometrium; meeting /conference /symposium; neoplasm /cancer genetics; travel; uterus neoplasms

DESCRIPTION (provided by applicant): Endometrial cancer is the most common gynecologic malignancy in the United States. Funding for endometrial cancer has traditionally lagged behind that for other gynecological tumors, such as cervical cancer and ovarian cancer. Consequently, in the past there has been a lack of a coordinated basic and translational research effort devoted to endometrial cancer. In 2003, a group of basic scientists and physician scientists from M.D. Anderson Cancer Center applied for and received NCI funding for an Endometrial Cancer SPORE. This group of investigators currently represents the only concentrated group of federally funded endometrial cancer researchers in the United States. For innovative, translational research in endometrial cancer to move forward, it will be necessary to bring together clinical investigators and laboratory scientists from a variety of different institutions across the country. Therefore, we propose to organize an annual Uterine Cancer Symposium with the following goals: 1) provide a meaningful forum to discuss cutting-edge developments in endometrial cancer biology; 2) attract experts in related fields (such as breast cancer and endocrinology) to encourage multi-disciplinary interactions; 3) promote collaborations between basic scientists and clinical investigators for the development of more innovative, high-impact translational research in endometrial cancer; and 4) encourage young, talented post-doctoral fellows, clinical residents/fellows, and faculty at the assistant professor level to enter the field of endometrial cancer research. The proposed Endometrial Cancer Symposium will be held on an annual basis in Houston, Texas. We successfully organized the 1st Uterine Cancer Biology Symposium in Houston in 2002, and we have a program of confirmed speakers for the 2nd Symposium to be held September 27 and 28, 2004. Topics for the annual Uterine Cancer Symposium series include hormonal mechanisms in endometrial cancer, molecular differences between aggressive (Type 2) and non-aggressive (Type 1) endometrial cancer, epidemiology of endometrial cancer, chemoprevention in high risk cohorts, endometrial hyperplasia/biomarkers of risk, mouse and cell culture models of endometrial cancer, and genetic events important in normal uterine development. For each symposium, a mixture of clinical topics and basic science topics will be presented to promote the development of quality translational research.

描述(申请人提供)：子宫内膜癌是美国最常见的妇科恶性肿瘤。传统上，对子宫内膜癌的资助落后于其他妇科肿瘤，如宫颈癌和卵巢癌。因此，在过去，一直缺乏致力于子宫内膜癌的协调的基础和翻译研究努力。2003年，一群来自M.D.安德森癌症中心的基础科学家和内科科学家申请并获得了NCI对子宫内膜癌孢子的资助。这组研究人员目前代表了美国唯一一组由联邦政府资助的子宫内膜癌研究人员。为了推进子宫内膜癌的创新性、转化性研究，有必要将来自全国各地不同机构的临床研究人员和实验室科学家聚集在一起。因此，我们建议每年组织一次子宫内膜癌研讨会，目标如下：1)提供一个有意义的论坛来讨论子宫内膜癌生物学的前沿发展；2)吸引相关领域的专家(如乳腺癌和内分泌学)，鼓励多学科互动；3)促进基础科学家和临床研究人员之间的合作，以开发更具创新性、高影响力的子宫内膜癌转化研究；以及4)鼓励年轻、有才华的博士后研究员、临床住院医师/研究员和助理教授水平的教师进入子宫内膜癌研究领域。提议的子宫内膜癌研讨会将每年在德克萨斯州的休斯顿举行。我们于2002年在休斯敦成功组织了首届子宫癌生物学研讨会，并为2004年9月27日和28日举行的第二届研讨会确定了演讲者计划。一年一度的子宫癌研讨会系列的主题包括子宫内膜癌的激素机制、侵袭性(2型)和非侵袭性(1型)子宫内膜癌之间的分子差异、子宫内膜癌的流行病学、高危人群中的化学预防、子宫内膜增生/风险的生物标志物、子宫内膜癌的小鼠和细胞培养模型，以及在正常子宫发育中重要的遗传事件。对于每一次研讨会，将提出混合的临床主题和基础科学主题，以促进高质量翻译研究的发展。